

Resource Summary Report

Generated by [RRID](#) on Aug 7, 2026

?-Actin (8H10D10) Mouse mAb

RRID:AB_2242334

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3700, RRID:AB_2242334

Antibody Information

URL: http://antibodyregistry.org/AB_2242334

Proper Citation: Cell Signaling Technology Cat# 3700, RRID:AB_2242334

Target Antigen: beta-actin

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IHC-P, IF-IC, F
Consolidation on 7/2016: AB_10828322.

Antibody Name: ?-Actin (8H10D10) Mouse mAb

Description: This monoclonal targets beta-actin

Target Organism: rat, hamster, mouse, human

Clone ID: 8H10D10

Antibody ID: AB_2242334

Vendor: Cell Signaling Technology

Catalog Number: 3700

Alternative Catalog Numbers: 3700P, 3700S

Record Creation Time: 20250820T055002+0000

Record Last Update: 20250820T223453+0000

Ratings and Alerts

- Used for immunohistochemistry by the Human Islet Research Network community. Contact(s): [Raghavendra Mirmira](#), [Amelia Linnemann](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for β -Actin (8H10D10) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 745 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Telonis AG, et al. (2026) Synergistic intragenic epigenetic deregulation by IDH2 and SRSF2 mutations causes mis-splicing of key transcriptional regulators. Science advances, 12(1), eadu8292.

Kolara LD, et al. (2026) IRE1 signaling in osteoprogenitors augments β -catenin activity and physiologic bone accrual. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 41(8), 890.

Brady MR, et al. (2026) Macropinocytosis and Vascularization Determine Response to mTOR Inhibitors in Lung Squamous Cell Carcinoma. Cancer research, 86(5), 1166.

Wang H, et al. (2026) Reversible dissociation of mitochondrial Complex V balances anabolic and energy-generating needs in cancer. iScience, 29(3), 114889.

Hermenejildo J, et al. (2026) Obesity as a Determinant of Periodontal Therapy Outcomes: Insights on Oxidative and Endoplasmic Reticulum Stress Pathways. International dental journal, 76(3), 109472.

Liu W, et al. (2026) Aerobic glycolysis promotes NLRP3 inflammasome activation via NLRP3 lactylation. Cell chemical biology, 33(2), 213.

Lin Q, et al. (2026) Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(11), 2279.

Mikolajewicz N, et al. (2026) Reactive oligodendrocytes promote glioblastoma progression through CCL5/CCR5-mediated glioma stem cell maintenance. Neuron, 114(2), 237.

McKimpson WM, et al. (2026) Activation of a Yap1-mesenchymal-like program in β -cells during diabetes. Cell reports, 45(7), 117596.

Yao J, et al. (2026) Activating an interleukin 4-FLT3-STAT6 axis in multipotent progenitors restores lymphopoiesis in inflammation and aging. Immunity, 59(7), 1843.

Wu Z, et al. (2026) TREM2 sustains glucose metabolic homeostasis to drive antibacterial defense during sepsis. *iScience*, 29(4), 115415.

Zavala MR, et al. (2026) An INF2-dependent actin-mediated step in inositol 1,4,5-trisphosphate receptor cluster formation and activity. *Current biology : CB*, 36(12), 3088.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Zheng S, et al. (2026) Chromosomal instability promotes cell migration and invasion via EFEMP1 secretion into extracellular vesicles. *The EMBO journal*, 45(10), 3471.

Balzano E, et al. (2026) Impact of Tau overexpression on DNA replication dynamics in centromeres of human neural progenitor cells. *iScience*, 29(2), 114707.

Pawar NR, et al. (2026) A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells. *Molecular cancer therapeutics*.

Mochizuki-Ono C, et al. (2026) PLA2G12A-driven extracellular vesicle-lipid signaling amplifies pathogenic T cell responses in inflammatory diseases. *Cell reports*, 45(6), 117391.

O'Toole KT, et al. (2026) Identification and characterization of BRAF?TP53 interactions in melanoma. *Cell reports*, 45(4), 117078.

Lim J, et al. (2026) Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity. *Science advances*, 12(19), eaea6842.

Reeb KL, et al. (2026) Structural and molecular determinants of glutamate transporter allosteric modulators. *Molecular pharmacology*, 108(5-6), 100122.